1. Kaatsch PaS, C. . German Childhood Cancer Registry - Report 2016 (1980-2015). Institute of Medical and Biostatistics, Epidemiology and Informatics (IMBEI) at the University Medical Center of the Johannes Gutenberg University Mainz. 2016.
2. Selle B, Furtwängler R, Graf N, Kaatsch P, Bruder E, Leuschner I. Population-based study of renal cell carcinoma in children in Germany, 1980-2005: More frequently localized tumors and underlying disorders compared with adult counterparts. Cancer. 2006;107(12):2906-14.
3. Vujanić GM, Apps JR, Moroz V, Ceroni F, Williams RD, Sebire NJ, et al. Nephrogenic rests in Wilms tumors treated with preoperative chemotherapy: The UK SIOP Wilms Tumor 2001 Trial experience. Pediatr Blood Cancer. 2017;64(11).
4. Breslow NE, Beckwith JB, Perlman EJ, Reeve AE. Age distributions, birth weights, nephrogenic rests, and heterogeneity in the pathogenesis of Wilms tumor. Pediatr Blood Cancer. 2006;47(3):260-7.
5. Beckwith JB, Kiviat NB, Bonadio JF. Nephrogenic rests, nephroblastomatosis, and the pathogenesis of Wilms' tumor. Pediatr Pathol. 1990;10(1-2):1-36.
6. Beckwith JB. Precursor lesions of Wilms tumor: Clinical and biological implications. Medical and pediatric oncology. 1993;21(3):158-68.
7. Beckwith JB. Nephrogenic rests and the pathogenesis of Wilms tumor: Developmental and clinical considerations. American Journal of Medical Genetics. 1998;79(4):268-73.
8. Furtwängler R, Schmolze M, Graber S, Leuschner I, Amann G, Schenk JP, et al. Pretreatment for Bilateral Nephroblastomatosis is an Independent Risk Factor for Progressive Disease in Patients with Stage V Nephroblastoma. Klin Padiatr. 2014;226(3):175-81.
9. Ortiz MV, Fernandez-Ledon S, Ramaswamy K, Forlenza CJ, Shukla NN, Kobos R, et al. Maintenance chemotherapy to reduce the risk of a metachronous Wilms tumor in children with bilateral nephroblastomatosis. Pediatric Blood & Cancer. 2019;66(1):4.
10. Vujanić GM, Sandstedt B, Harms D, Kelsey A, Leuschner I, De Kraker J. Revised International Society of Paediatric Oncology (SIOP) working classification of renal tumors of childhood. Medical and pediatric oncology. 2002;38(2):79-82.
11. Rohrschneider WK, Weirich A, Rieden K, Darge K, Tröger J, Graf N. US, CT and MR imaging characteristics of nephroblastomatosis. Pediatric Radiology. 1998;28(6):435-43.
12. Reinhard H, Semler O, Bürger D, Bode U, Flentje M, Göbel U, et al. Results of the SIOP 93-01/GPOH trial and study for the treatment of patients with unilateral nonmetastatic wilms tumor. Klinische Padiatrie. 2004;216(3):132-40.
13. Furtwängler R, Gooskens SL, van Tinteren H, de Kraker J, Schleiermacher G, Bergeron C, et al. Clear cell sarcomas of the kidney registered on International Society of Pediatric Oncology (SIOP) 93-01 and SIOP 2001 protocols: a report of the SIOP Renal Tumour Study Group. Eur J Cancer. 2013;49(16):3497-506.
14. Sandberg JK, Chi YY, Smith EA, Servaes S, Hoffer FA, Mullen EA, et al. Imaging Characteristics of Nephrogenic Rests Versus Small Wilms Tumors: A Report From the Children's Oncology Group Study AREN03B2. AJR American journal of roentgenology. 2020;214(5):987-94.
15. Vujanic GM, Gessler M, Ooms A, Collini P, Coulomb-l'Hermine A, D'Hooghe E, et al. The UMBRELLA SIOP-RTSG 2016 Wilms tumour pathology and molecular biology protocol. Nature reviews Urology. 2018;15(11):693-701.
16. Schenk JP, Schrader C, Zieger B, Furtwängler R, Leuschner I, Ley S, et al. Reference radiology in nephroblastoma: Accuracy and relevance for preoperative chemotherapy. RoFo Fortschritte auf dem Gebiet der Rontgenstrahlen und der Bildgebenden Verfahren. 2006;178(1):38-45.
17. Welter N, Wagner A, Furtwängler R, Melchior P, Kager L, Vokuhl C, et al. Characteristics of Nephroblastoma/Nephroblastomatosis in Children with a Clinically Reported Underlying Malformation or Cancer Predisposition Syndrome. Cancers. 2021;13(19):5016.
18. Brioude F, Kalish JM, Mussa A, Foster AC, Bliek J, Ferrero GB, et al. Expert consensus document: Clinical and molecular diagnosis, screening and management of Beckwith-Wiedemann syndrome: an international consensus statement. Nat Rev Endocrinol. 2018;14(4):229-49.
19. Bisogno G, de Kraker J, Weirich A, Masiero L, Ludwig R, Tournade MF, et al. Veno-occlusive disease of the liver in children treated for Wilms tumor. Med Pediatr Oncol. 1997;29(4):245-51.
20. Termuhlen AM, Tersak JM, Liu Q, Yasui Y, Stovall M, Weathers R, et al. Twenty-five year follow-up of childhood Wilms tumor: a report from the Childhood Cancer Survivor Study. Pediatr Blood Cancer. 2011;57(7):1210-6.
21. Jagt CT, Zuckermann M, Ten Kate F, Taminiau JA, Dijkgraaf MG, Heij H, et al. Veno-occlusive disease as a complication of preoperative chemotherapy for Wilms tumor: A clinico-pathological analysis. Pediatr Blood Cancer. 2009;53(7):1211-5.
22. Caiulo VA, Latini G, Cataldi L, De Felice C. Nephrogenic rests: their frequency and their fate. J Pediatr Hematol Oncol. 2007;29(6):361-3.
23. van den Heuvel-Eibrink MM, Hol JA, Pritchard-Jones K, van Tinteren H, Furtwangler R, Verschuur AC, et al. Position paper: Rationale for the treatment of Wilms tumour in the UMBRELLA SIOP-RTSG 2016 protocol. Nature reviews Urology. 2017;14(12):743-52.
24. Coppes MJ, Arnold M, Beckwith JB, Ritchey ML, D'Angio GJ, Green DM, et al. Factors affecting the risk of contralateral Wilms tumor development: A report from the national Wilms tumor study group. Cancer. 1999;85(7):1616-25.
25. Bergeron C, Iliescu C, Thiesse P, Bouvier R, Dijoud F, Ranchere-Vince D, et al. Does nephroblastomatosis influence the natural history and relapse rate in Wilms' tumour? A single centre experience over 11 years. European journal of cancer. 2001;37(3):385-91.
26. Friesenbichler W, Krizmanich W, Lakatos K, Attarbaschi A, Dworzak M, Amann G, et al. Outcome of two patients with bilateral nephroblastomatosis/Wilms tumour treated with an add-on 13-cis retinoic acid therapy - Case report. Pediatr Hematol Oncol. 2018;35(3):218-24.
27. Ehrlich P, Chi YY, Chintagumpala MM, Hoffer FA, Perlman EJ, Kalapurakal JA, et al. Results of the First Prospective Multi-institutional Treatment Study in Children With Bilateral Wilms Tumor (AREN0534): A Report From the Children's Oncology Group. Ann Surg. 2017;266(3):470-8.
28. Witt O, Hämmerling S, Stockklausner C, Schenk JP, Günther P, Behnisch W, et al. 13-cis retinoic acid treatment of a patient with chemotherapy refractory nephroblastomatosis. Journal of Pediatric Hematology/Oncology. 2009;31(4):296-9.
29. Perlman EJ, Faria P, Soares A, Hoffer F, Sredni S, Ritchey M, et al. Hyperplastic perilobar nephroblastomatosis: Long-term survival of 52 patients. Pediatric Blood and Cancer. 2006;46(2):203-21.
30. Van Den Heuvel-Eibrink MM, Van Tinteren H, Bergeron C, Coulomb-L'Hermine A, De Camargo B, Leuschner I, et al. Outcome of localised blastemal-type Wilms tumour patients treated according to intensified treatment in the SIOP WT 2001 protocol, a report of the SIOP Renal Tumour Study Group (SIOP-RTSG). European Journal of Cancer. 2015;51(4):498-506.
31. Vujanic GM, Harms D, Sandstedt B, Weirich A, de Kraker J, Delemarre JF. New definitions of focal and diffuse anaplasia in Wilms tumor: the International Society of Paediatric Oncology (SIOP) experience. Medical and pediatric oncology. 1999;32(5):317-23.
32. Scalabre A, Bergeron C, Brioude F, Dainese L, Cropet C, Coulomb L'hermine A, et al. Is Nephron Sparing Surgery Justified in Wilms Tumor With Beckwith-Wiedemann Syndrome or Isolated Hemihypertrophy? Pediatr Blood Cancer. 2016;63(9):1571-7.
33. Brok J, Lopez-Yurda M, Tinteren HV, Treger TD, Furtwangler R, Graf N, et al. Relapse of Wilms' tumour and detection methods: a retrospective analysis of the 2001 Renal Tumour Study Group-International Society of Paediatric Oncology Wilms' tumour protocol database. Lancet Oncol. 2018;19(8):1072-81.
34. Vuononvirta R, Sebire NJ, Dallosso AR, Reis-Filho JS, Williams RD, Mackay A, et al. Perilobar nephrogenic rests are nonobligate molecular genetic precursor lesions of insulin-like growth factor-II-associated Wilms tumors. Clin Cancer Res. 2008;14(23):7635-44.
35. Hol JA, Jongmans MCJ, Sudour-Bonnange H, Ramirez-Villar GL, Chowdhury T, Rechnitzer C, et al. Clinical characteristics and outcomes of children with WAGR syndrome and Wilms tumor and/or nephroblastomatosis: The 30-year SIOP-RTSG experience. Cancer. 2021;127(4):628-38.
36. Günther P, Tröger J, Graf N, Waag KL, Schenk JP. MR volumetric analysis of the course of nephroblastomatosis under chemotherapy in childhood. Pediatric Radiology. 2004;34(8):660-4.
37. Royer-Pokora B. Genetics of pediatric renal tumors. Pediatric Nephrology. 2013;28(1):13-23.
38. Telander RL, Gilchrist GS, Burgert EO, Jr., Kelalis PP, Goellner JR. Bilateral massive nephroblastomatosis in infancy. J Pediatr Surg. 1978;13(2):163-6.
39. Haddy TB, Bailie MD, Bernstein J, Kaufman DB, Rous SN. Bilateral, diffuse nephroblastomatosis: report of a case managed with chemotherapy. J Pediatr. 1977;90(5):784-6.
40. de Chadarevian JP, Fletcher BD, Chatten J, Rabinovitch HH. Massive infantile nephroblastomatosis: a clinical, radiological, and pathological analysis of four cases. Cancer. 1977;39(5):2294-305.
41. Ehrlich PF, Tornwall B, Chintagumpala MM, Chi YY, Hoffer FA, Perlman EJ, et al. Kidney Preservation and Wilms Tumor Development in Children with Diffuse Hyperplastic Perilobar Nephroblastomatosis: A Report from the Children's Oncology Group Study AREN0534. Annals of surgical oncology. 2022.